scientific reports

Detoxification of hydrogen OPEN sulfide by synthetic heme model compounds

Atsuki Nakagami1, Qiyue Mao1, Masaki Horitani2,3, Masahito Kodera1 & Hiroaki Kitagishi1

Hydrogen sulfide is a lethal toxic gas that disrupts cellular respiration in the mitochondrial system. Currently, no antidote is available for the clinical treatment of hydrogen sulfide poisoning. In this study, we investigated the function of iron(III)porphyrin complexes as hydrogen sulfide scavengers in water and evaluated their potential use as therapeutic agents for hydrogen sulfide poisoning. The compounds, named met-hemoCD-P and met-hemoCD-I, are composed of iron(III)porphyrin complexed with per-methylated β-cyclodextrin dimers that contain a pyridine (met-hemoCD-P) or imidazole axial fifth ligand that is coordinated to Fe(III) (met-hemoCD-I). These compounds formed stable HS– Fe(III) complexes under physiological conditions, with binding constants of 1.2×105 and 2.5×10⁶ M–1 for met-hemoCD-P and met-hemoCD-I, respectively. The binding constant of met-hemoCD-I was 10-times higher than that reported for native human met-hemoglobin at pH 7.4 and 25oC. Electron paramagnetic resonance (EPR) spectroscopy and H₂S quantification assays revealed that after SH⁻ **was coordinated to met-hemoCD-I, it was efficiently converted to nontoxic sulfite and sulfate ions via homolytic cleavage of the HS–Fe(III) bond followed by aerobic oxidation. Mouse animal experiments revealed that the survival rate was significantly improved when NaSH-treated mice were injected with met-hemoCD-I. After the injection, mitochondrial C***c***O function in brain and heart tissues recovered, and met-hemoCD-I injected was excreted in the urine without chemical decomposition.**

Keywords Hydrogen sulfide, Heme, Porphyrin, Cyclodextrin, Injectable antidote

Hydrogen sulfide (H2 S) is a colorless, flammable, and hazardous gas with a rotten egg smell. The toxic effect of H2 S is similar to that of hydrogen cyanide (HCN), which strongly binds to cytochrome *c* oxidase (C*c*O) in the mitochondrial respiratory chain; thus, H_2S is classified as a cellular asphyxiant^{[1](#page-12-0)-5}. As its specific gravity (1.19) is greater than that of air, H₂S tends to accumulate at lower altitudes, often causing poisoning accidents at sites such as in manholes, sewage systems, and mining operations^{[1](#page-12-0)[,6](#page-12-2)}. Although there are fewer than 10 cases of industrial H₂S poisoning per year in Japan, 220 cases with 208 deaths were reported in 2007 in Japan due to suicide by intentional H_2S generation, which is known as the detergent suicide pandemic^{[6,](#page-12-2)[7](#page-12-3)}. The following year, this method of suicide was observed in the United States and worldwide^{[8](#page-12-4),[9](#page-12-5)}. Frighteningly, residual H₂S gas often spreads from the source or victim and causes secondary poisoning to the rescue personnel and/or individuals at the site^{8,[9](#page-12-5)}. No clinical antidote is currently available for H_2S poisoning. Therefore, ready-to-use antidotes that can be stored for long durations and are immediately effective are greatly needed, especially for situations involving emergency rescue.

The administration of heme proteins or artificial heme-model compounds may be a promising approach for the development of antidotes against poisoning caused by inhaled gases such as H_2S , which reacts with metalloproteins (including hemoglobin) in red blood cells (RBCs)^{[10](#page-12-6)[,11](#page-12-7)}. For this purpose, the compounds should exhibit higher binding affinities toward toxins than native hemes. Relying on this strategy, researchers have proposed potential antidotes for carbon monoxide (CO), hydrogen cyanide (HCN), and H_2S poisoning using native and modified heme proteins as well as natural vitamin B_{12} analogs^{[4](#page-12-8)[,12](#page-12-9)–18}. However, few studies have established antidote systems using synthetic compounds^{[12](#page-12-9),19}. Therefore, our group developed synthetic hememodel compounds composed of iron tetrakis(4-sulfonatophenyl)porphyrin (FeTPPS) complexes encapsulated by per-*O*-methylated β-cyclodextrin (CD) dimers^{[20](#page-12-12)–22}. Figure [1](#page-1-0) shows two representative CD dimers, Py3CD and Im3CD, that form inclusion complexes with Fe(III)TPPS to yield met-hemoCD-P and met-hemoCD-I,

¹Department of Molecular Chemistry and Biochemistry, Faculty of Science and Engineering, Doshisha University, 1-3 Tatara Miyakodani, Kyotanabe-city, Kyoto 610-0321, Japan. 2Department of Applied Biochemistry and Food Science, Faculty of Agriculture, Saga University, 1 Honjo-machi, Saga 840-8502, Japan. 3The United Graduate School of Agricultural Science, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan. \mathbb{Z} email: hkitagis@mail.doshisha.ac.jp

Fig. 1. Chemical structures of cyclodextrin dimers Py3CD and Im3CD and met-hemoCD-P and methemoCD-I in combination with iron(III)porphyrin (Fe(III)TPPS) in aqueous saline solution.

respectively. We have shown that reduced hemoCD-P in the ferrous state functions as an internal CO scavenger in vivo 21,23 21,23 21,23 21,23 and that met-hemoCD-I functions as a potential cyanide antidote^{[24,](#page-12-16)[25](#page-12-17)}. When these heme model compounds were injected intravenously or intraperitoneally into mice or rats, they bound gaseous molecules in the circulation system^{[21–](#page-12-14)25}. Interestingly, these compounds were rapidly and quantitatively excreted in the urine through renal clearance; thus, they do not accumulate in the body. Therefore, compared to native protein-based scavenging systems, our system shows potential as an injectable antidote.

In the present study, we investigated the potential of met-hemoCD-P and met-hemoCD-I as hydrogen sulfide scavengers. Using the ferric forms of these two complexes, we first present the basic reactivity toward hydrogen sulfide in aqueous solution in view of thermodynamic and kinetic parameters and spectroscopic characterizations. Then, the antidote effect against hydrogen sulfide-induced intoxication was tested in mice.

Results

Binding of hydrogen sulfide to met-hemoCD-P and met-hemoCD-I

In this study, we used sodium hydrogen sulfide (NaSH) as the sulfide source. In aqueous media, SH– equilibrates with H₂S, and the p*K*_a is 6.98 at 25 °C and 6.76 at 37 °C^{[26](#page-12-18)[,27](#page-12-19)}. The presence of S^{2–} could be negligible under aqueous conditions due to the low acidity of SH[–] (p*K*_a = 19 ± 2).^{[26](#page-12-18),27} In this article, we use the term "hydrogen sulfide" to refer to both H2 S and SH– species. The binding constants (*K*) of hydrogen sulfide to met-hemoCD-I and met-hemoCD-P were evaluated by UV-vis spectroscopic titration. Upon the addition of NaSH, the spectra of met-hemoCD-P and met-hemoCD-I changed stepwise with clear isosbestic points (Fig. [2](#page-2-0)). The spectral changes were saturated at approximately one equivalent of added NaSH. The spectral characters of these complexes were shown in Figures S1 and S2. In the absence of CD dimers, Fe(III)TPPS was decomposed by the addition of NaSH (Figure S3A)[28,](#page-12-20)[29](#page-12-21)[,45.](#page-13-0) Similar porphyrin decomposition was also observed for Fe(III)TPPS complexed with 2,3,6-tri-*O*-methyl-β-CD (TMe-β-CD), which lacks an axial fifth ligand (Figure S3B). This result suggested that, in addition to protection by the CD cavity, pyridine or imidazole ligation in Py3CD or Im3CD contributed to the formation of a stable HS–Fe(III)porphyrin complex.

The titration curves were well fitted to the 1:1 equilibrium model, affording *K* values of 1.2×10^5 M⁻¹ and 2.5×10^6 2.5×10^6 M⁻¹ for met-hemoCD-P and met-hemoCD-I, respectively, in phosphate buffer at pH 7.4 (Fig. 2). The kinetic parameters for the binding of hydrogen sulfide were determined by time-resolved UV-vis spectral measurements (Fig. [3](#page-3-0)). Single/double-exponential curve fitting analysis was used to determine the apparent association rate constants (\bar{k}_{on} ^{app}, the fast component in the double-exponential fitting analysis (>80%)). The second-order rate constants (k_{on}) were determined via linear regression of the k_{on}^{app} values as a function of [NaSH] (Fig. [4A](#page-4-0) and B). The parameters were strongly dependent on the pH of the solution (Figure S4 and S5). As listed in Table [1](#page-4-1), met-hemoCD-I exhibits higher *K* and k_{on} values than those of met-hemoCD-P. The plot of k_{on} and k_{off} values versus pH (Fig. [4C](#page-4-0) and D) clearly shows the high ability of met-hemoCD-I to act as a hydrogen sulfide scavenger at physiological pH (7.4). Hydrogen sulfide binds more quickly to met-hemoCD-I at neutral pH because the p K_a (p K_a^{H2O} = 7.7) of the axial aqua ligand is higher than that of hemoCD-P (p K_a^{H2O} = 5.5).^{[22,](#page-12-13)[24](#page-12-16)}

Fig. 2. Spectroscopic analysis of the binding of hydrogen sulfide to (**A**) met-hemoCD-P (5 µM) and (**B**) methemoCD-I (5 μ M) in 0.05 M phosphate buffer solution at pH 7.4 and 25 °C. Changes in the UV-vis absorption spectra of (a) met-hemoCD-P and (d) met-hemoCD-I upon the addition of NaSH. The initial spectrum is shown in blue, and the final spectrum is shown in red. The differential spectra of (b) met-hemoCD-P and (e) met-hemoCD-I upon the addition of NaSH. The plots of the absorbance changes versus [NaSH] of (c) methemoCD-P and (f) met-hemoCD-I. The solid lines are the best fit of the data to an equation for 1:1 complex formation to give the binding constants (*K*).

A continuous variation plot (Job plot) was constructed for the met-hemoCD-I and NaSH systems (Figure S6). The maximum complexation ratio observed at a 1:1 molar ratio clearly indicates that a 1:1 complex of methemoCD-I and NaSH was present; these results indicate that poly(sulfide) complexes such as $HS(S)_{n}$ –Fe(II), which are often proposed in biological systems, were not detected $1¹$. Additionally, electrospray ionization timeof-flight mass spectrometry (ESI-TOF-MS) revealed that the HS–Fe(III) complex in met-hemoCD-I formed (Figure S7). The molecular ion peak of met-hemoCD-I (MW=3947.9) was detected at 1315.4 (*m*/*z*) as a tri-

Fig. 3. UV-vis absorption spectra collected over time in the reaction of (A)met-hemoCD-P (5 µM) and (**B**) met-hemoCD-I (5 µM) with excess NaSH in 0.05 M phosphate buffer solution at pH 7.4 and 25 °C. The initial spectrum is shown in blue, and the final spectrum is shown in red. The differential spectra of (b) methemoCD-P and (e) met-hemoCD-I upon the addition of NaSH. The time-course traces at 410 nm (black) and the fitted curve (red) according to a single/double exponential function to derive the observed rate constants (k_{obs}) for (c) met-hemoCD-P and (f) met-hemoCD-I.

anionic species. With NaSH, the molecular ion peak of met-hemoCD-I was mainly detected at 995.1 (*m*/*z*), which could be assigned to HS-bound met-hemoCD-I (MW = 3981.0) in the tetra-anionic form. These results revealed that a stable 1:1 complex of met-hemoCD-I with hydrogen sulfide (HS–Fe(III)porphyrin) formed in aqueous media at physiological pH.

Oxidative degradation of hydrogen sulfide by met-hemoCD-I

In the presence of excess NaSH (100 equivalents), met-hemoCD-I gradually degraded under aerobic conditions (Fig. [5A](#page-5-0) and S8). The degradation was significantly suppressed under anaerobic conditions with a Soret band at

Fig. 4. Kinetic analysis of the binding between hydrogen sulfide and met-hemoCDs. (**A**,**B**) Plots of *k*obs for met-hemoCD-P and met-hemoCD-I as a function of [NaSH]. The solid lines represent linear least-square fitting of the data, which provided the k_{on} values. (C,D) Plots of k_{on} and k_{off} for met-hemoCD-P and methemoCD-I as a function of pH.

	met -hemoCD- P			met-hemoCD-I		
pH	$K(M^{-1})$	k_{on} $(M^{-1}s^{-1})$	$k_{\text{off}}(s^{-1})$	$K(M^{-1})$	$k_{\rm on}$ $(M^{-1}s^{-1})$	$k_{\text{off}}(s^{-1})$
6.0	$(9.0 \pm 2.6) \times 10^6$	$(1.5 \pm 0.1) \times 10^3$	$(1.7 \pm 1.0) \times 10^{-4}$	$(6.9 \pm 2.0) \times 10^5$	$(2.2 \pm 0.6) \times 10^3$	$(3.2 \pm 1.0) \times 10^{-3}$
7.0			$\left[\left(2.9 \pm 1.0\right) \times 10^5 \right]$ $\left(3.8 \pm 0.3\right) \times 10^2$ $\left(1.3 \pm 0.4\right) \times 10^{-3}$ $\left(2.7 \pm 0.8\right) \times 10^6$ $\left(1.8 \pm 0.4\right) \times 10^3$ $\left(6.6 \pm 2.0\right) \times 10^{-4}$			
7.4	$(1.2 \pm 0.4) \times 10^5$		(1.0 ± 0.1) x 10 ² (8.4 ± 3.0) x 10 ⁻⁴ (2.5 ± 0.7) x 10 ⁶ (1.5 ± 0.8) x 10 ³ (5.9 ± 1.0) x 10 ⁻⁴			
8.0	$(3.0 \pm 1.0) \times 10^{4}$		$(4.0 \pm 1.0) \times 10^{1}$ $(1.5 \pm 0.5) \times 10^{-3}$ $(6.7 \pm 2.0) \times 10^{5}$ $(7.2 \pm 4.4) \times 10^{2}$ $(1.1 \pm 0.3) \times 10^{-3}$			

Table 1. Binding constants (*K*) and rate constants (k_{on} , k_{off}) of met-hemoCD-P and met-hemoCD-I with hydrogen sulfide in 0.05 M phosphate buffer at different pH values and at 25 °C.

434 nm, indicating that a ferrous hemoCD-I complex formed in the deoxy form[30.](#page-13-1) To confirm the iron oxidation state, carbon monoxide (CO) gas was introduced into the solution after met-hemoCD-I was mixed with NaSH (Fig. [5B](#page-5-0), S9 and S10). A sharp Soret band appeared at 423 nm, which is characteristic of the CO–Fe(II) complex. Therefore, homolytic bond cleavage of the HS–Fe(III) complex occurred, generating a sulfide radical (HS•) and Fe(II) complex of hemoCD-I. In the presence of molecular oxygen (O_2) , the reduced Fe(II) complex formed the O_2 adduct, which was readily autoxidized to ferric met-hemoCD-I with the generation of superoxide^{31-[33](#page-13-3)}. The autoxidation rate of the O₂ adduct for hemoCD-I ($t_{1/2} \sim 36$ min at 37 °C) is much faster than that for ferrous hemoCD-P ($t_{1/2} \sim 5$ h at 37 °C)²⁵. Therefore, the reaction cycle of met-hemoCD-I with hydrogen s

Fig. 5. Reaction of met-hemoCD-I with hydrogen sulfide in 0.05 M phosphate buffer solution at pH 7.4. (A) Changes in the UV-vis absorption spectra of met-hemoCD-I (5 μ M) (black line) after the addition of excess NaSH under aerobic (red lines) and anaerobic (blue lines) conditions at 25 °C. (**B**) UV-vis absorption spectra of met-hemoCD-I (5 μ M) before and after two molar equivalents of NaSH were added at 25 °C. After the formation of HS-hemoCD-I complex, the solution was bubbled with CO gas right after the CO-ferrous complexes were formed. (**C**) Proposed pathway for the catalytic decomposition of hydrogen sulfide with methemoCD-I. (**D**) EPR spectral changes of met-hemoCD-I before and after NaSH (two equivalents) was added. The reagents were mixed and incubated at 25 °C, and the spectra were measured in the frozen state at 5 K.

under aerobic conditions should proceed faster than met-hemoCD-P. In addition, as the autoxidation of oxyhemoCD-I became fast in the presence of SH– (Figure S11), there are multiple pathways of sulfide consumption in this system as the overall scheme is summarized in Fig. [5](#page-5-0)C.

To further characterize the reaction of met-hemoCD-I with NaSH, electron paramagnetic resonance (EPR) spectra of met-hemoCD-I were obtained before and after the reaction of NaSH at physiological pH and 5 K (Fig. [5](#page-5-0)D). Before the reaction with NaSH occurred, met-hemoCD-I showed EPR signals at *g*=6.03, 2.30, and 2.00. The signals at *g*=6.03 and 2.00 could be assigned to the characteristic signals of 5-coordinated high-spin iron(III)porphyrin with or without a weakly coordinated sixth ligand, such as H2 O, while the signal at *g*=2.30 could be assigned to the iron(III)porphyrin coordinated with a hydroxoligand³⁴. Immediately after NaSH was added, characteristic signals at *g*=2.41, 2.20, and 1.92 were generated due to the HS–Fe(III)–N(imidazole) 6-coordinated low-spin complex^{[35](#page-13-5)-37}. The EPR signals became almost silent when the solution was incubated for an hour and then frozen after NaSH was added, indicating that an EPR-inactive ferrous Fe(II) complex formed due to the homolysis of HS–Fe(III). Ferric high-spin species of met-hemoCD-I were detected after 2 and 3 h of incubation. The time-course change in the EPR spectra confirmed that met-hemoCD-I was converted to the ferrous Fe(II) complex via HS–Fe(III) complex formation, as proposed in Fig. [5](#page-5-0)C.

The hydrogen sulfide species in aqueous solution decomposed rapidly in the presence of met-hemoCD-I (Fig. [6A](#page-6-0)). The efficacy of hydrogen sulfide decomposition is correlated with binding parameters for methemoCD-I, met-hemoCD-P, and met-Hb, as summarized in Table [2.](#page-6-1) Consistently, sulfite and sulfate ions were produced efficiently in the presence of O_2 with met-hemoCD-I (Fig. [6B](#page-6-0)). The control data under anaerobic

Fig. 6. Degradation of hydrogen sulfide in 0.05 M phosphate buffer solution at pH 7.4. (**A**) Time course changes in the residual amount of hydrogen sulfide (initial: 1.0 mM) in solutions containing met-hemoCD-I, met-hemoCD-P, and met-Hb (50 µM each). The residual sulfide was detected by the methylene blue method (see [Materials and Methods](#page-10-0) section). (**B**) Production of sulfite and sulfate ions during the reaction between hydrogen sulfide and met-hemoCD-I. The aqueous solution of hydrogen sulfide (9 mM) was mixed with met-hemoCD-I (0.45 mM) and incubated for 1 h. The sulfite and sulfate ions were detected by the addition of barium chloride and quantified by the solution turbidity (see Experimental section). Each bar represents the mean±SE (*n*=3). The asterisks denote statistical significance, ****P*<0.005. ***P*<0.01.

Table 2. Binding constants (K) and rate constants $(k_{\text{on}}, k_{\text{off}})$ of met-hemoCD, met-Hb and met-Mb with hydrogen sulfide in aqueous buffer at pH 7.4 and 25 °C. *^a* Ref. 37. *^b* Ref. 38. *^c* The kinetic parameters were recalculated as a function of the hydrogen sulfide (H2 S/SH–) concentration. *^d*Data obtained at 37 °C. *^e* Data obtained at 20 °C. f Na₂S was used as a sulfide source.

conditions support the involvement of O_2 in met-hemoCD-I-assisted decomposition of hydrogen sulfide. Other sulfide compounds such as polysulfides and thiosulfate could be produced as previously reported³⁷ but were not quantified in this study. Turbidimetric assay using barium ions supports the formation of BaSO₃ and BaSO₄ as the precipitates. The significant production of sulfite and sulfate ions in the presence of met-hemoCD-I under anaerobic conditions would be derived from high affinity of hemoCD-I against O_2 . The $P_{1/2}$ ^{O2} value of 1.7 Torr for hemoCD-I is much smaller than that of hemoCD-P $(10$ Torr)^{[22](#page-12-13)}. A small amount of residual oxygen could bind to met-hemoCD-I, which causes production of these anions even under anaerobic conditions.

Strength of met-hemoCD-I antidotes for hydrogen sulfide poisoning in mice

We then evaluated the strength of met-hemoCD-I antidotes for hydrogen sulfide in mice. As shown in the survival curve of the mice in Fig. [7A](#page-7-0), the intraperitoneal injection of NaSH (21 mg/kg) into the mice caused significant lethal toxicity. When 7 mM met-hemoCD-I aqueous solution (0.2 mL) was intraperitoneally injected prior to NaSH injection, the survival curve significantly improved, indicating the efficacy of NaSH detoxification. The antidote effect was also significant when met-hemoCD-I was injected immediately after the mice were poisoned with NaSH (Fig. [7](#page-7-0)B). Therefore, met-hemoCD-I is effective before and after poisoning with NaSH.

The lactate level in the blood was increased by NaSH but returned to normal by met-hemoCD-I (Fig. [8A](#page-8-0)). Therefore, anaerobic metabolism caused by NaSH was recovered in mice by the injection of met-hemoCD-I. More directly, we investigated the activity of C*c*O in organs (Fig. [8](#page-8-0)B–D). In brain and heart tissues, the NaSHinduced decrease in C*c*O activity returned to normal in the met-hemoCD-I-treated mice, whereas no significant

A) Pre-dosing

Fig. 7. Survival curves for NaSH-treated mice treated with or without met-hemoCD-I. (**A**) Predosing. A solution of met-hemoCD-I (7 mM, 0.2 mL) in PBS was intraperitoneally injected into the mice, followed by an intraperitoneal injection of NaSH (21 mg/kg). (**B**) Postdosing. A solution of NaSH (21 mg/kg) in PBS was intraperitoneally injected into the mice, followed by an intraperitoneal injection of met-hemoCD-I (7 mM, 0.2 mL). The asterisks denote statistical significance, ***P*<0.01.

B) Post-dosing

change was observed in the liver. Overall, these analyses support that met-hemoCD-I injection protects against hydrogen sulfide-induced asphyxial death in mice.

After met-hemoCD-I was injected, dark red urine was obtained from the mice within 60 min. The UV-vis spectrum of the urine showed the characteristic Soret and Q bands of met-hemoCD-I (Fig. [9](#page-9-0)). The spectral simulation revealed that the urine contained 80% met-hemoCD-I and 20% CO-hemoCD-I. Ferrous hemoCD-I could be formed by a natural reduction system in the body³⁹ and/or the homolytic cleavage of the HS–Fe(III) bond in hemoCD-I formed during circulation. Ferrous hemoCD-I bound to endogenous CO in the circulation and was subsequently excreted. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectroscopic analysis of urine revealed no changes in the Im3CD structure (Fig. [9](#page-9-0) inset). The inclusion complex of met-hemoCD-I was dissociated upon laser irradiation according to MALDI-TOF mass spectrometry. These results indicate that injected met-hemoCD-I in mice was excreted in the urine without chemical changes. Injected met-hemoCD-I could react with hydrogen sulfide and metabolize the compound to sulfite and/or sulfate during circulation, then return to the met-form via the mechanism proposed in Fig. [5](#page-5-0)C.

Discussion

In this work, we investigated the use of met-hemoCD-P and met-hemoCD-I as hydrogen sulfide receptors in aqueous solution and in vivo. Compared to native Hb and Mb, met-hemoCD-I showed a greater binding rate and affinity toward hydrogen sulfide; therefore, we concluded that met-hemoCD-I is an effective and ready-touse antidote for hydrogen sulfide-induced poisoning. Here, we discuss the binding of hydrogen sulfide to our heme-model system and compare it with that of other potential antidotes.

The binding of hydrogen sulfide to metal ions in proteins, including heme proteins, has been proposed in many studies^{[10,](#page-12-6)[11](#page-12-7)}. However, compared to that of O₂, CO, and cyanide, detailed characterizations of HS–metal complexes with thermodynamic and kinetic parameters have been limited in the several literatures 40 . Among the native systems, the interactions between ferric Hb and Mb with hydrogen sulfide have been characterized in detail[37](#page-13-6)[,38](#page-13-9). As reported in these studies, the binding parameters strongly depend on the pH of the solutions. The binding is relatively fast at low pH, and under these conditions, hydrogen sulfide presents as H_2S . Interestingly, the pH dependency is reversed for a small heme protein, MP-11⁴¹, in which the heme cofactor is exposed to the aqueous bulk phase. These data indicate that the preferable attacking species, H_2S or SH^- , should differ depending on the environment around the iron center of the heme⁴². In the hemoCD system, the binding parameters were also dependent on pH, similar to those of Hb and Mb, indicating that hydrophobic H_2S tends to enter the iron(III) site located in the CD cavity. In contrast, we confirmed that a stable 1:1 complex of iron(III)porphyrin formed with SH–. The net charge of the iron(III)porphyrin ring becomes zero upon SH– ligation (four negative charges of peripheral sulfonate locate outside the cyclodextrin's cavity).The electronically neutralized porphyrin should be stable in the hydrophobic cavity provided by the CD dimer; thus, this force drives anion binding to iron(III)porphyrin–methylated CD complexes in water⁴³. Hydrophobic H₂S is easily accessible to the iron(III) center of met-hemoCD, followed by deprotonation to SH– to neutralize the net charge of iron(III)porphyrin. The pH-dependent binding character is explained by the state of hydrogen sulfide (H2 S or SH–) and the axial ligand species on the iron(III) center before binding. Met-hemoCD-I has an exchangeable aqua ligand at neutral pH

Fig. 8. Effect of met-hemoCD-I antidotes on mice poisoned by NaSH. (**A**) Lactate levels in the blood of mice treated with NaSH followed by met-hemoCD-I. (**B**–**D**) Cytochrome *c* oxidase (C*c*O) activity in the brain (**B**), heart (**C**), and liver (**D**) of mice treated with NaSH followed by met-hemoCD-I. In the model, a solution of NaSH (21 mg/kg) in PBS was intraperitoneally injected into mice, followed by an intraperitoneal injection of met-hemoCD-I (7 mM, 0.2 mL). Each bar represents the mean±SE (*n*≧3). The asterisks denote statistical significance, ****P*<0.005. ***P*<0.01, **P*<0.05.

Fig. 9. UV-vis absorption spectrum of urine (black) excreted from mice treated with NaSH (21 mg/kg) followed by met-hemoCD-I (7 mM, 0.2 mL). The spectra of met-hemoCD-I (green) and CO-hemoCD-I (orange) are shown for comparison. The red dotted line shows the accumulated spectra of met-hemoCD-I (80%) and CO-hemoCD-I (20%), which were consistent with those of urine. The inset shows MALDI-TOF mass spectra of Im3CD and urine with subsequent addition of α-cyano-4-hydroxycinamic acid (positive mode). The calculated molecular weight (M) of Im3CD is 2961.4.

due to its p*K*_a^{H2O} (7.7), whereas met-hemoCD-P (p*K*_a^{H2O} = 5.5) has a strongly coordinated hydroxo ligand on iron(III) at neutral pH. Therefore, met-hemoCD-I, which exhibits a higher p*K*_a^{H2O} than that of met-hemoCD-P, bound more quickly to hydrogen sulfide under physiological conditions; thus, met-hemoCD-I could be superior to met-hemoCD-P as a hydrogen sulfide receptor in vivo.

The interaction between hydrogen sulfide and synthetic iron(III) porphyrins has been investigated through biomimetic chemistry. In the system that involves a picket-fence-type Fe/Cu binuclear porphyrin complex, electrocatalytic O₂ reduction on the gold electrode was inhibited at a high concentration of H₂S in a reversible manner⁴⁴. This result suggests the toxic mechanism by which H_2S inhibits the native mitochondrial CcO system. Another study using picket-fence porphyrins in nonaqueous media revealed that stable HS–Fe(III)porphyrin complexes formed via a 1:1 reaction with the SH– anion[45.](#page-13-0) A synthetic heme-peptide conjugate model was also synthesized as an MP-11 model and formed a 6-coordinated HS–Fe(III) low-spin species in water⁴⁶. Atmospheric oxygen causes the porphyrins to significantly decompose, which is common in these model studies; thus, these HS–Fe(III)porphyrin complexes have been characterized under anaerobic conditions. Due to the difficulty in preparing HS–heme species, a stable synthetic model with the $R_3Si-S-Fe(III)$ complex has been proposed for detailed structural characterization⁴⁷. To our knowledge, in presence of oxygen, there are few artificial synthetic models for the binding between hydrogen sulfide and iron-porphyrins in water except for our previous study using the hemoCD system^{[36](#page-13-16)}. Importantly, in our model, once hydrogen sulfide bound to the met-hemoCDs, the porphyrin ring was significantly protected against oxidative degradation induced by SH– owing to the CD cavity and axial fifth coordination. Due to its high stability, the bound SH– anion could be efficiently converted to sulfite and sulfate ions via oxidation by atmospheric O_2 . This oxidative conversion from hydrogen sulfide to sulfite, sulfate and thiosulfate ions or polysulfides has been similarly reported in the native Hb and Mb systems^{[35](#page-13-5),[37,](#page-13-6)[48](#page-13-17)}, in which the heme cofactors are also protected in the hydrophobic heme pockets provided by apo-proteins. Therefore, due to the protection of the porphyrin ring by the CD dimer, we efficiently detoxified hydrogen sulfide under physiological conditions. Furthermore, in contrast to Mb and Hb, injected met-hemoCD is easily excreted in the urine due to its small molecular weight, which is another advantage of the present antidote system.

Currently, no antidote is available to clinically treat H_2S poisoning, but several approaches have been proposed to detoxify hydrogen sulfide in animals and clinical trials. As the toxic mechanism is almost identical to that of hydrogen cyanide, vitamin B_{12} analogs (hydroxocobalamin and cobinamide), which are used as cyanide antidotes, are effective treatments for hydrogen sulfide poisoning^{[4,](#page-12-8)[17](#page-12-22),[49,](#page-13-18)[50](#page-13-19)}. Intravenously injected vitamin B_{12} analogs can capture hydrogen sulfide during circulation, after which it is strongly captured by serum proteins

and accumulates for a long period (over a month)^{[24](#page-12-16)[,51](#page-13-20)}. Therefore, patients that receive high doses of vitamin B₁₂ analogs may need to avoid strong light exposure due to the photosensitizing property of cobalamins. Oxidized Hb (met-Hb) could function as an antidote for hydrogen sulfide. Sodium nitrite (NaNO₂), which is an oxidizing agent that produces met-Hb in circulating RBCs, has been shown to exhibit an antidote effect on hydrogen sulfide⁵². However, this method cannot be easily adjusted to the met-Hb ratio (%) in RBCs. In another recent trial using met-Hb, a met-Hb-albumin cluster was injected and markedly improved the survival rate of mice¹⁸. Compared to these potential candidates, the hemoCD system is advantageous because (1) met-hemoCD-I shows greater binding affinity toward hydrogen sulfide than that of met-Hb and met-Mb, and (2) the hemoCD compound injected is quantitatively excreted in urine within several hours. Therefore, met-hemoCD-I can effectively capture H_2S , and after detoxification, injected met-hemoCD-I easily disappears from the body through renal clearance. In a previous study, ferrous hemoCD-P injected into mice or rats was quantitatively detected in the CO-bound form in urine^{[21](#page-12-14),[23,](#page-12-15)[25](#page-12-17)}. However, for hydrogen sulfide, HS-bound met-hemoCD-I was not detected in the urine. Instead, met-hemoCD-I was mainly detected without change because the bound hydrogen sulfide on met-hemoCD-I in the body could be smoothly converted to sulfite or sulfate ions via catalytic oxidation with O_2 , as demonstrated in this study.

We recently reported an antidote system for CO and cyanide mixed intoxication using hemoCD-Twins, a mixture of hemoCD-P and hemoCD-I in the ferrous state²⁵. It is well known that CO and HCN are generated as lethal toxic gases during building fires. Previous studies in mice demonstrated that CO and HCN exhibit a synergetic lethal effect, which was counteracted by hemoCD-Twins. Interestingly, when hemoCD-Twins was injected into mice, hemoCD-P remained ferrous and could capture CO, while hemoCD-I was oxidized during circulation, and met-hemoCD-I detoxified cyanide. In general, CO poisoning can be quickly diagnosed by pulse CO oximetry or blood gas analysis. On the other hand, HCN in blood is difficult to detect rapidly at the site of accidents. The dual antidote system with hemoCD-Twins is advantageous because it can be injected without determination of which gas the patient primarily inhaled. Additionally, in this study, met-hemoCD-I clearly detoxified hydrogen sulfide. Although hydrogen sulfide is rarely produced in fire accidents, hemoCD-Twins are the first choice for patients that are potentially poisoned by an unknown gas. As the injected hemoCD complex is smoothly excreted in urine, it can be employed without a risk of side effects due to accumulated compounds. We are attempting to apply this detoxification system using hemoCD-Twins in clinical practice.

In conclusion, synthetic heme model compounds composed of iron(III)porphyrin and a per-*O*-methylated cyclodextrin dimer were found to bind to hydrogen sulfide and form a stable HS–Fe(III) complex. Furthermore, met-hemoCD-I catalytically and efficiently decomposed hydrogen sulfide into nontoxic sulfite/sulfate ions under physiological conditions. Mouse animal experiments revealed that met-hemoCD-I exhibits excellent properties as a novel antidote for hydrogen sulfide poisoning. We expect that this hemoCD-based system will serve as a ready-to-use, multifunctional gas poisoning antidote that can simultaneously remove CO, cyanide, and hydrogen sulfide via a single injection.

Materials and methods Materials

Met-HemoCD-P and met-hemoCD-I were synthesized in our laboratory as described in previous reports²⁵. We used sodium hydrogen sulfide (NaSH) as a hydrogen sulfide source. NaSH was purchased from Stream Chem. Inc. Before the use of NaSH, its purity was determined by iodometric titration 36 . All other reagents were purchased and used as received. The solution was deoxidized by N_2 -bubbling for 30 min prior to anaerobic experiments.

Preparation of the NaSH solution

 Since NaSH is easily oxidized in water, we prepared a stock solution of NaSH before each application. Milli-Q water was deoxidized by nitrogen gas bubbling for 30 min. Then, NaSH was solubilized in deoxidized water and used as a stock solution. Once a NaSH solution was prepared, it was used within 3 h. The concentration of NaSH in solution, *C* [mM], was determined as follows:

$$
C \text{ [mM]} = \left\{ \left(x \text{ [mg]} \times y \text{ [%]} \times 10^3 \right) / \left(56.063 \left[\text{g} \cdot \text{mol}^{-1} \right] \times z \text{ [mL]} \right) \right\}
$$

where *x* is the weight of NaSH, *y* is the purity of NaSH determined by iodometric titration as described above, and *z* is the volume of the stock solution. The purity of NaSH was 93%.

Instruments

UV-vis spectra were recorded on a Shimadzu UV-2450 spectrophotometer with a thermostatic cell holder. Kinetic studies were carried out using a JASCO FS-110 Fast Scan Spectrometer with a thermostatic cell holder. EPR measurements were obtained with a Bruker E500 spectrometer at the Institute for Molecular Science in continuous-wave (CW) mode operating at ~9.66 GHz and equipped with an Oxford Instruments ESR900 continuous helium flow cryostat. The experimental parameters were 5 mW microwave power, 100 kHz field modulation, and 10 G modulation amplitude. MALDI-TOF mass spectra were measured on Bruker Daltonics Autoflex speed spectrometers in positive mode. α-Cyano-4-hydroxycinnamic acid (CHCA) was used as the matrix. ESI-TOF mass spectra were taken on a JEOL JMS-T100CS spectrometer.

Spectroscopic measurements

 The binding constants (*K*) of hydrogen sulfide to met-hemoCD-P and met-hemoCD-I were determined by UV-vis photometric titration. NaSH (up to 50 μ M) was added to an aerobic solution of met-hemoCD-I or methemoCD-P (5 μM) at 25 °C in 0.05 M phosphate buffer at pH 6.0, 7.0, 7.4 and 8.0. The absorbance changes at the wavelength with maximum change in differential spectrum versus [NaSH] were plotted, and the data were fitted to a theoretical curve of an equation for 1:1 complex formation to obtain *K*.

The association rate constants (k_{on}) for the binding of hydrogen sulfide to met-hemoCD-P and methemoCD-I were obtained under pseudo-first-order conditions with excess NaSH at 25 °C. An aerobic solution of met-hemoCD-P or met-hemoCD-I (5 µM) was mixed rapidly with various concentrations of NaSH (100–1400 µM before mixing) in 0.05 M phosphate buffer at pH 7.0, 7.4 or 8.0. The change in absorbance at 410 nm was monitored, and the data were fitted to a single or double exponential function to obtain the observed rates k_{obs} . When the reaction between met-hemoCD and hydrogen sulfide was too fast $(k_{obs} > 0.5)$, a double exponential fitting was required due to an unknown slow reaction component. In that case, the component of k_{fast} occupied more than 80% of the total. In addition, that ratio was independent of pH. Therefore, we adopted k_{fast} as the actual k_{obs} (reaction between met-hemoCDs and hydrogen sulfide), while k_{slow} is possibly due to the reaction between met-hemoCDs and impurities derived from NaSH, such as polysulfides⁵³. Finally, the k_{on} values were obtained from linear regression of k_{obs} as a function of the hydrogen sulfide concentration. Concerning the binding parameters, we determined k_{off} from *K* and k_{on} ($K = k_{\text{on}}/k_{\text{off}}$). On the other hand, it should also be possible to determine k_{off} from y-intercept of the k_{obs} vs. [NaSH] plot ($k_{\text{obs}} = k_{\text{on}}$ [NaSH] + k_{off}). However, the estimated *k*_{off} values obtained from the plot seemed much larger than those determined based on *K* (Table [1](#page-4-1)). This is possibly due to the difference of the binding/dissociation species; as the k_{on} values became larger in lower pH, the binding species should be ascribed to undissociated H2 S. Deprotonation after the binding results in the formation of HS–Fe(III) complexes. The k_{off} value based on K should be the dissociation of SH[–] from the HS-Fe(III), whereas k_{off} from the y-intercept of the k_{obs} plot is assumed to be the H₂S–Fe(III) species. Therefore, the k_{off} values from the y-intercept became much larger than those based on *K*. However, we avoid discussing this point in detail because the value from y-intercept generally includes large error (over 100%).

Quantification of hydrogen sulfide

An aqueous solution of NaSH (1.0 mM) was mixed with met-hemoCD or met-Hb (50 μ M) and incubated at 25 °C. The residual hydrogen sulfide concentrations were determined using the reported "methylene blue" method with some modifications^{[54,](#page-13-23)[55](#page-13-24)}. The solution containing hydrogen sulfide and its scavenger was diluted to 2.5 mL with 0.05 M phosphate buffer at pH 7.4 to adjust the total hydrogen sulfide concentration to less than 50 µM. To the solution was added trifluoroacetic acid (0.5 mL). Then, solutions of *N*, *N*-dimethyl-*p*phenylenediamine sulfate (200 mM stock solution, 30 μ L) dissolved in HClaq (7.2 mM) and FeCl₃ (300 mM) stock solution, 30 µL) dissolved in 1.2 mM HCl were added successively. The solutions were allowed to stand for 20 min at ambient room temperature. Finally, the absorbance at 663 nm was read, and the hydrogen sulfide concentration was determined based on the standard curve of methylene blue.

Quantification of sulfate and sulfite

 The relative production rate of sulfate and sulfite ions from hydrogen sulfide was determined by a simple turbidimetric method, in which the amount of sulfate (SO_4^{2-}) was quantified by turbidity through the following reaction:⁵⁶.

$$
SO_4^{2-} + \text{BaCl}_2 \rightarrow \text{BaSO}_4 \downarrow + 2Cl^-
$$

The average absorbance between 700 nm and 800 nm was used as turbidity, where met-hemoCD-I and other scavengers showed no absorbance in the area. The turbidity showed a linear correlation with the sulfate concentration from 0.5 mM to 4.0 mM upon the addition of 1.5 equivalents of BaCl₂. We also confirmed that sulfite (SO₃²) ions form a similar insoluble precipitate of BaSO₃ with BaCl₂ as follows:⁵⁷.

$$
SO_3^{2-} + \text{BaCl}_2 \rightarrow \text{BaSO}_3 \downarrow + 2Cl^-
$$

Therefore, the relative production of sulfate and sulfite ions in solution was simply determined by reading the average absorbance between 700 nm and 800 nm after treatment of the solution with BaCl_{2} .

Animal experiments

 All animal studies were performed under the approval of Doshisha University and the animal experiments including all methods were carried out in accordance with the Guidelines for Animal Experiments of Doshisha University. We used female BALB/cCrSlc mice (Shimizu Laboratory Supplies, Co., Ltd.) weighing 20–22 g. The study is reported in accordance with ARRIVE guidelines and AVMA guidelines for the Euthanasia of Animals (2020). For acclimatization, the mice were housed under a 12 h/12 h light/dark cycle with free feedings under specific-pathogen-free (SPF) conditions for one week before the day in the experiments. The mice were euthanized using cervical dislocation method by a well-trained experimenter.

For survival analysis of met-hemoCD-I in lethal hydrogen sulfide intoxication model mice, a solution of NaSH (21 mg/kg) in PBS (0.1 mL) was injected intraperitoneally under unanesthesia. One minute after the injection of NaSH, a solution of met-hemoCD-I (7 mM) in PBS (0.2 mL) was injected intraperitoneally. For the predosing experiments, a solution of met-hemoCD-I (7 mM) in PBS (0.2 mL) was injected intraperitoneally. After 10 min, a solution of NaSH (21 mg/kg) in PBS (0.1 mL) was injected intraperitoneally. Survival rates were then monitored for one hour after hydrogen sulfide intoxication was induced.

We determined the C*c*O activity and the concentration of lactate in the blood of lethal hydrogen sulfide intoxication model mice. Tissue samples (brain, heart, and liver) were collected from met-hemoCD-I-treated surviving mice one hour after hydrogen sulfide intoxication was induced. As a control, we collected tissue samples (brain, heart, and liver) from untreated mice immediately after death. The CcO activity in these

organs was determined by the following method according to the literature⁵⁸. Each tissue sample (\sim 20 mg) was homogenized in 0.5 mL of sucrose muscle homogenization buffer (250 mM). Then, the suspension was centrifuged at 600 g for 10 min at 4°C. The supernatant (5 µL) was added to a 1 mL cuvette which contains 400 µL of Milli-Q water, 500 µL of potassium phosphate buffer (0.1 M, pH 7.0) and 50 µL of reduced cytochrome *c* (Product name; ab109911, abcam, UK). The absorbance at 550 nm was read for 3 min. The rate of activity (OD/min) was determined by calculating the slope between two points within the linear region. Finally, the CcO activity was determined by normalizing the rate activity by its protein amount in tissue using BCA assay (Thermo Fisher Scientific, Japan). The concentration of lactate in the blood was measured using LT-1730 Lactate Pro2 (Arkray).

Statistical analysis

 Statistical analyses were performed using GraphPad Prism, version 10.2.3 (GraphPad Software). All the data are presented as the means \pm standard errors from at least three different experiments and were analyzed by Student's t test. Survival curves were analyzed using Kaplan-Meier curves and the log-rank test. Differences with *P* values less than 0.05 were considered significant.

Data availability

All relevant data are in the manuscript.

Received: 17 June 2024; Accepted: 19 November 2024 Published online: 10 December 2024

References

- 1. Maldonado, C. S., Weir, A. & Rumbeiha, W. K. A comprehensive review of treatments for hydrogen sulfide poisoning: past, present, and future. *Toxicol. Mech. Methods*. **33**, 183–196 (2023).
- 2. Cuevasanta, E., Möller, M. N. & Alvarez, B. Biological chemistry of hydrogen sulfide and persulfides. *Arch. Biochem. Biophys.* **617**, 9–25 (2017).
- 3. Olson, K. R. & Straub, K. D. The role of hydrogen sulfide in evolution and the evolution of hydrogen sulfide in metabolism and signaling. *Physiology* **31**, 60–72 (2016).
- 4. Jiang, J. et al. Hydrogen sulfide–mechanisms of toxicity and development of an antidote. *Sci. Rep.* **6**, 20831 (2016).
- 5. Blackstone, E., Morrison, M. & Roth, M. B. H2 S induces a suspended animation-like state in mice. *Science* **22**, 518 (2005). 6. Morii, D., Miyagatani, Y., Nakamae, N., Murao, M. & Taniyama, K. Japanese experience of hydrogen sulfide: the suicide craze in
- 2008. *J. Occup. Med. Toxicol.* **5**, 28 (2010).
- 7. Iseki, K., Ozawa, A., Seino, K., Goto, K. & Tase, C. The suicide pandemic of hydrogen sulfide poisoning in Japan. *Asia Pac. J. Med. Toxicol.* **3**, 13–17 (2013).
- 8. Reedy, S. J. D., Schwartz, M. D. & Morgan, B. W. Suicide fads: frequency and characteristics of hydrogen sulfide suicides in United States. *West. J. Emerg. Med.* **12**, 300–304 (2011).
- 9. Adkins, J. Hydrogen sulfide suicide: Latest technique hazardous to first responders and the public. Special Research Report in Regional Organized Crime Information Center. <https://npstc.org/documents/H2S%20Report%20for%204112.pdf>
- 10. Pietri, R., Román-Morales, E. & López-Garriga, J. Hydrogen sulfide and hemeproteins: knowledge and mysteries. *Antioxid. Redox Signal.* **15**, 393–404 (2011).
- 11. Domán, A. et al. Interactions of reactive sulfur species with metalloproteins. *Redox Biol.* **60**, 102617 (2023).
- 12. Parker, A. L. & Johnstone, T. C. Carbon monoxide poisoning: a problem uniquely suited to a medical inorganic chemistry solution. *J. Inorg. Biochem.* **251**, 112453 (2024).
- 13. Azarov, I. et al. Five-coordinate H64Q neuroglobin as a ligand-trap antidote for carbon monoxide poisoning. *Sci. Transl Med.* **8**, 368ra173 (2016).
- 14. Rose, J. J. et al. A neuroglobin-based high-affinity ligand trap reverses carbon monoxide–induced mitochondrial poisoning. *J. Biol. Chem.* **295**, 6357–6371 (2020).
- 15. Xu, Q. et al. Cell-free and alkylated hemoproteins improve survival in mouse models of carbon monoxide poisoning. *JCI Insight*. **7**, e153296 (2022).
- 16. Chan, A. et al. Nitrocobinamide, a new cyanide antidote that can be administered by intramuscular injection. *J. Med. Chem.* **58**, 1750–1759 (2015).
- 17. Fujita, Y. et al. A fatal case of acute hydrogen sulfide poisoning caused by hydrogen sulfide: hydroxocobalamin therapy for acute hydrogen sulfide poisoning. *J. Anal. Toxicol.* **35**, 119–123 (2011).
- 18. Suzuki, Y. et al. Methemoglobin-albumin clusters for the treatment of hydrogen sulfide intoxication. *J. Control Release*. **349**, 304– 314 (2022).
- 19. Droege, D. G. & Johnstone, T. C. A water-soluble iron-porphyrin complex capable of rescuing CO-poisoned red blood cells. *Chem. Comm.* **58**, 2722–2725 (2022).
- 20. Kano, K., Kitagishi, H., Kodera, M. & Hirota, S. Dioxygen binding to a simple myoglobin model in aqueous solution. *Angew Chem. Int. Ed.* **44**, 435–438 (2005).
- 21. Kitagishi, H. et al. Kano K. A diatomic molecule receptor that removes CO in a living organism. *Angew Chem. Int. Ed.* **49**, 1312– 1315 (2010).
- 22. Kitagishi, H. & Kano, K. Synthetic heme protein models that function in aqueous solution. *Chem. Commun.* **57**, 148–173 (2021).
- 23. Kitagishi, H. et al. Feedback response to selective depletion of endogenous carbon monoxide in the blood. *J. Am. Chem. Soc.* **138**, 5417–5425 (2016).
- 24. Watanabe, K., Kitagishi, H. & Kano, K. Supramolecular ferric porphyrins as cyanide receptors in aqueous solution. *ACS Med. Chem. Lett.* **2**, 943–947 (2011).
- 25. Mao, Q. et al. A synthetic porphyrin as an effective dual antidote against carbon monoxide and cyanide poisoning. *Proc. Natl. Acad. Sci. U.S.A.* 120, e2209924120 (2023).
- 26. Li, Q. & Lancaster, J. R. Jr. Chemical foundations of hydrogen sulfide biology. *Nitric Oxide*. **35**, 21–34 (2013).
- 27. Hughes, M. N., Centelles, M. N. & Moore, K. P. Making and working with hydrogen sulfide: the chemistry and generation of hydrogen sulfide in vitro and its measurement in vivo: a review. *Free Radic Biol. Med.* **47**, 1346–1353 (2009).
- 28. Lente, G. & Fábián Kinetics and mechanism of the oxidation of water soluble porphyrin Fe^{III}TPPS with hydrogen peroxide and the peroxomonosulfate ion. *Dalton Trans.* **38**, 4268–4275 (2007).
- 29. Kitagishi, H. et al. Oxoferryl porphyrin/hydrogen peroxide system whose behavior is equivalent to hydroperoxoferric porphyrin. *J. Am. Chem. Soc.* **132**, 16730–16732 (2010).
- 30. Kano, K., Kitagishi, H., Mabuchi, T., Kodera, M. & Hirota, S. A myoglobin functional model composed of a ferrous porphyrin and a cyclodextrin dimer with an imidazole linker. *Chem. Asian J.* **1**, 358–366 (2006).
- 31. Shikama, K. The molecular mechanism of autoxidation for myoglobin and hemoglobin: a venerable puzzle. *Chem. Rev.* **98**, 1357– 1374 (1998).
- 32. Shikama, J. Stability properties of dioxygen-iron(II) porphyrins: an overview from simple complexes to myoglobin. *Coord. Chem. Rev.* **83**, 73–91 (1988).
- 33. Kano, K. et al. Iron porphyrin-cyclodextrin supramolecular complex as a functional model of myoglobin in aqueous solution. *Inorg. Chem.* **45**, 4448–4460 (2006).
- 34. Sono, M. & Dawson, J. H. Formation of low spin complexes of ferric cytochrome P-450-CAM with anionic ligands. *J. Biol. Chem.* **257**, 5469–5502 (1982).
- 35. Vitvitsky, V., Yadav, P. K., Kurthen, A. & Banerjee, R. Sulfide oxidation by a noncanonical pathway in red blood cells generates thiosulfate and polysulfides. *J. Biol. Chem.* **290**, 8310–8320 (2015).
- 36. Watanabe, K., Suzuki, T., Kitagishi, H. & Kano, K. Reaction between a haemoglobin model compound and hydrosulphide in aqueous solution. *Chem. Commun.* **51**, 4059–4061 (2015).
- 37. Bostelaar, T., Vitvitsky, V. & Kumutima, J. Hydrogen sulfide oxidation by myoglobin. *J. Am. Chem. Soc.* **138**, 8476–8488 (2016).
- 38. Jensen, B. & Fago, A. Reactions of ferric hemoglobin and myoglobin with hydrogen sulfide under physiological conditions. *J. Inorg. Biochem.* **182**, 133–140 (2018).
- 39. Noguchi, M., Mao, Q., Nakagami, A. & Kitagishi, H. Spontaneous reduction of iron(III)porphyrin to iron(II)porphyrin–CO complex in mouse circulation. *Chem. Commun.* **59**, 6211–6214 (2023).
- 40. Boubeta, F. M. et al. Hemoproteins as targets for sulfide species. *Antioxid. Redox Signal.* **32**, 247–257 (2020).
- 41. Boubeta, F. M. et al. Mechanism of sulfide binding by ferric hemeproteins. *Inorg. Chem.* **57**, 7591–7600 (2018).
- 42. Boubeta, F. M., Bari, S. E., Estrin, D. A. & Boechi, L. Access and binding of H2 S to hemeproteins: the case of Hbl of *Lucina pectinata*. *J. Phys. Chem. B*. **120**, 9642–9653 (2016).
- 43. Kano, K., Kitagishi, H., Tamura, S. & Yamada, A. Anion binding to a ferric porphyrin complexed with per-*O*-methylated β-cyclodextrin in aqueous solution. *J. Am. Chem. Soc.* **126**, 15202–15210 (2004).
- 44. Collman, J. P., Ghosh, S., Dey, A. & Decréau, R. A. Using a functional enzyme model to understand the chemistry behind hydrogen sulfide induced hibernation. *Proc. Natl. Acad. Sci. U.S.A.* 106, 22090–22095 (2009).
- 45. Hartle, M. D., Prell, J. S. & Pluth, M. D. Spectroscopic investigations into the binding of hydrogen sulfide to synthetic picket-fence porphyrins. *Dalton Trans.* **45**, 4843–4853 (2016).
- 46. Zhao, Z. et al. Proximal environment controlling the reactivity between inorganic sulfide and heme-peptide model. *RSC Adv.* **6**, 78858–78864 (2016).
- 47. Meininger, D. J., Caranto, J. D., Arman, H. D. & Tonzetich, Z. J. Studies of iron(III) porphyrins containing silanethiolate ligands. *Inorg. Chem.* **52**, 12468–12476 (2013).
- 48. Vitvitsky, V. et al. Structural and mechanistic insights into hemoglobin-catalyzed hydrogen sulfide oxidation and the fate of polysulfide products. *J. Biol. Chem.* **292**, 5584–5592 (2017).
- 49. Ng, P. C. & Hendry-Hofer, T. Intramuscular cobinamide versus saline for treatment of severe hydrogen sulfide toxicity in swine. *Clin. Toxicol*. **57**, 189–196 (2019).
- 50. Haouzi, P., Chenuel, B. & Sonobe, T. High dose hydroxocobalamin administered after H_2 S exposure counteracts sulfide poisoning induced cardiac depression in sheep. *Clin. Toxicol. (Phila)*. **53**, 28–36 (2015).
- 51. Marques, H. M., Brown, K. L. & Jacobsen, D. W. Kinetics and activation parameters of the reaction of cyanide with free aquocobalamin and aquocobalamin bound to a haptocorrin from chicken serum. *J. Biol. Chem.* 263, 12378–12383 (1988).
- 52. Hoidal, C. R., Hall, A. H., Robinson, M. D., Kulig, K. & Rumack, B. H. Hydrogen sulfide poisoning from toxic inhalations of roofing asphalt fumes. *Ann. Emerg. Med.* **15**, 826–830 (1988).
- 53. Greiner, R. et al. Polysulfides link H₂S to protein thiol oxidation. *Antioxid. Redox Signal.* **19**, 1749–1765 (2013).
- 54. Lawrence, N. S., Davis, J. & Compton, R. G. Analytical strategies for the detection of sulfide: a review. *Talanta* **52**, 771–784 (2000).
- 55. Morikawa, T. et al. Hypoxic regulation of the cerebral microcirculation is mediated by a carbon monoxide-sensitive hydrogen sulfide pathway. *Proc. Natl. Acad. Sci. U.S.A.* 109, 1293–1298 (2012).
- 56. Coleman, R. L., Shults, W. D., Kelly, M. T. & Dean, J. A. Turbidimetry via parallel photometric analysis. Determination of sulfate. *Anal. Chem.* **44**, 1031–1034 (1972).
- 57. Müller, I. A., Brunner, B., Breuer, C., Coleman, M. & Bach, W. The oxygen isotope equilibrium fractionation between sulfite species and water. *Geochim. Cosmochim. Acta*. **120**, 562–581 (2013).
- 58. Spinazzi, M., Casarin, A., Pertegato, V., Salviati, L. & Angelini, C. Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. *Nat. Protoc.* **7**, 1235–1246 (2012).

Author contributions

H.K. conceived the study. A.N. and Q.M. performed the main experiments and analyzed the data. M.H. performed the electron paramagnetic resonance spectroscopy experiments. M.K. provided useful suggestions for advancing this research. A.N. and H.K. wrote the manuscript. All authors participated in the revision of the manuscript.

Funding

This work was funded by JSPS KAKENHI (22H02097 and 24K01640), AMED (23ym0126814 and 24ym0126808j), and JST (JPMJSF2305, JPMJSP2129). A part of this work was conducted at the Institute for Molecular Science, supported by Nanotechnology Platform Program < Molecule and Material Synthesis > JPMXP1224MS1025 (to M.H.) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.

Declarations

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at [https://doi.org/1](https://doi.org/10.1038/s41598-024-80511-1) [0.1038/s41598-024-80511-1.](https://doi.org/10.1038/s41598-024-80511-1)

Correspondence and requests for materials should be addressed to H.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit<http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024